ClinicalTrials.gg
TerminatedNCT00168792Updated Oct 29, 2013

A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)

A Phase 4 interventional study of Tenecteplase and PCI in Myocardial Infarction, sponsored by Boehringer Ingelheim. Terminated at 177 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-29.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,671
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Myocardial Infarction by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Myocardial Infarction · Boehringer Ingelheim.

Started
2003
with 1 other
Phase 4
Only one
of the 12
Registered
2nd of 12
by date

Among the 12 studies in Myocardial Infarction by Boehringer Ingelheim, this one is one of 2 that started in 2003, is the only one in phase 4, and was the 2nd registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

None of the 12 studies in Myocardial Infarction by Boehringer Ingelheim is open now. The open studies under Myocardial Infarction, anywhere →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Myocardial Infarction by Boehringer Ingelheim as a file.
02

Study summary

To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute myocardial infarcts as compared to primary PCI alone.

03

Conditions studied

  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients giving
  • Patients with a large acute myocardial infarction randomised within 6 hours of symptom onset
  • Patients scheduled to undergo primary PCI
  • Patients reaching the cath lab not before 60 min and not later than 3 hours after randomisation

(Otherwise the patients fulfill the usual selection criteria for thrombolytic treatment and PCI)

Exclusion Criteria: None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,671 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Death or cardiogenic shock or congestive heart failure within 90 days

    Time frame: 90 days

Secondary outcomes

  1. Death or cardiogenic shock or congestive heart failure within 30 days

    Time frame: 30 days

  2. Cardiogenic shock or congestive heart failure within 90 days

    Time frame: 90 days

  3. Death

    Time frame: 90 days

  4. Cardiogenic shock

    Time frame: 90 days

  5. Reinfarction

    Time frame: 90 days

  6. Repeat target vessel revascularisation (TVR)

    Time frame: 90 days

  7. Rehospitalisation for congestive heart failure

    Time frame: 90 days

  8. Rehospitalisation for cardiogenic shock

    Time frame: 90 days

  9. Rehospitalisation for other cardiac reasons

    Time frame: 90 days

  10. Congestive heart failure

    Time frame: 90 days

  11. N-terminal pro-brain natriuretic peptide (NT pro-BNP)

    Time frame: 90 days

  12. Disabling stroke

    Time frame: 90 days

  13. Total stroke

    Time frame: 90 days

  14. Rehospitalisation for stroke or ICH (intrancranial haemorrhage)

    Time frame: 90 days

07

Study locations

177 sites
  • Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • Boehringer Ingelheim Investigational Site
    Fort Lauderdale, Florida, United States
  • Boehringer Ingelheim Investigational Site
    St. Petersburg, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Tampa, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Macan, Georgia, United States
  • Boehringer Ingelheim Investigational Site
    Detroit, Michigan, United States
  • Boehringer Ingelheim Investigational Site
    Omaha, Nebraska, United States
  • Boehringer Ingelheim Investigational Site
    Providence, Rhode Island, United States
  • Boehringer Ingelheim Investigational Site
    Feldkirch, Austria
  • Boehringer Ingelheim Investigational Site
    St. Pölten, Austria
  • Boehringer Ingelheim Investigational Site
    Wien, Austria
  • Boehringer Ingelheim Investigational Site
    Wr. Neustadt, Austria
  • Boehringer Ingelheim Investigational Site
    Aalst, Belgium
  • Boehringer Ingelheim Investigational Site
    Antwerpen, Belgium
  • Boehringer Ingelheim Investigational Site
    Bonheiden, Belgium
  • Boehringer Ingelheim Investigational Site
    Brugge, Belgium
  • Boehringer Ingelheim Investigational Site
    Brussel, Belgium
  • Boehringer Ingelheim Investigational Site
    Bruxelles / Anderlecht, Belgium
  • Boehringer Ingelheim Investigational Site
    Bruxelles, Belgium
  • Boehringer Ingelheim Investigational Site
    Charleroi, Belgium
  • Boehringer Ingelheim Investigational Site
    Genk, Belgium
  • Boehringer Ingelheim Investigational Site
    Gent, Belgium
  • Boehringer Ingelheim Investigational Site
    Gilly, Belgium
  • Boehringer Ingelheim Investigational Site
    Huy, Belgium
  • Boehringer Ingelheim Investigational Site
    La Louvière, Belgium
  • Boehringer Ingelheim Investigational Site
    Leuven, Belgium
  • Boehringer Ingelheim Investigational Site
    Liège-Angleur, Belgium
  • Boehringer Ingelheim Investigational Site
    Liège, Belgium
  • Boehringer Ingelheim Investigational Site
    Namur/Bouge, Belgium
  • Boehringer Ingelheim Investigational Site
    Namur, Belgium
  • Boehringer Ingelheim Investigational Site
    Roeselare, Belgium
  • Boehringer Ingelheim Investigational Site
    Blumenau - SC, Brazil
  • Boehringer Ingelheim Investigational Site
    Curitiba - PR, Brazil
  • Boehringer Ingelheim Investigational Site
    Marília - SP, Brazil
  • Boehringer Ingelheim Investigational Site
    Passo Fundo - RS, Brazil
  • Boehringer Ingelheim Investigational Site
    Porto Alegre - RS, Brazil
  • Boehringer Ingelheim Investigational Site
    São Paulo - SP, Brazil
  • Boehringer Ingelheim Investigational Site
    Victoria, British Columbia, Canada
  • Boehringer Ingelheim Investigational Site
    Saint-Foy, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Sudbury, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Montreal, Quebec, Canada
  • Boehringer Ingelheim Investigational Site
    Regina, Saskatchewan, Canada
  • Boehringer Ingelheim Investigational Site
    Saskatoon, Saskatchewan, Canada
  • Boehringer Ingelheim Investigational Site
    Pardubice, Czech Republic
  • Boehringer Ingelheim Investigational Site
    Prague 4-Krc, Czech Republic
  • Boehringer Ingelheim Investigational Site
    Prague 5, Czech Republic
  • Boehringer Ingelheim Investigational Site
    Aulnay sous Bois, France
  • Boehringer Ingelheim Investigational Site
    Brest, France
  • Boehringer Ingelheim Investigational Site
    Caen, France
  • Boehringer Ingelheim Investigational Site
    Châteauroux, France
  • Boehringer Ingelheim Investigational Site
    Clermont-Ferrand, France
  • Boehringer Ingelheim Investigational Site
    Colmar, France
  • Boehringer Ingelheim Investigational Site
    Créteil, France
  • Boehringer Ingelheim Investigational Site
    Lille, France
  • Boehringer Ingelheim Investigational Site
    Lorient, France
  • Boehringer Ingelheim Investigational Site
    Lyon, France
  • Boehringer Ingelheim Investigational Site
    Marseille, France
  • Boehringer Ingelheim Investigational Site
    Massy, France
  • Boehringer Ingelheim Investigational Site
    Metz, France
  • Boehringer Ingelheim Investigational Site
    Montfermeil, France
  • Boehringer Ingelheim Investigational Site
    Montpellier, France
  • Boehringer Ingelheim Investigational Site
    Nice, France
  • Boehringer Ingelheim Investigational Site
    Nîmes, France
  • Boehringer Ingelheim Investigational Site
    Paris, France
  • Boehringer Ingelheim Investigational Site
    Perpignan, France
  • Boehringer Ingelheim Investigational Site
    Pontoise, France
  • Boehringer Ingelheim Investigational Site
    Saint Etienne, France
  • Boehringer Ingelheim Investigational Site
    Strasbourg, France
  • Boehringer Ingelheim Investigational Site
    Bad Friedrichshall, Germany
  • Boehringer Ingelheim Investigational Site
    Bad Kreuznach, Germany
  • Boehringer Ingelheim Investigational Site
    Bassum, Germany
  • Boehringer Ingelheim Investigational Site
    Bautzen, Germany
  • Boehringer Ingelheim Investigational Site
    Berlin-Lichtenberg, Germany
  • Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • Boehringer Ingelheim Investigational Site
    Bingen, Germany
  • Boehringer Ingelheim Investigational Site
    Bonn, Germany
  • Boehringer Ingelheim Investigational Site
    Boppard, Germany
  • Boehringer Ingelheim Investigational Site
    Bremen, Germany
  • Boehringer Ingelheim Investigational Site
    Böblingen, Germany
  • Boehringer Ingelheim Investigational Site
    Dresden, Germany
  • Boehringer Ingelheim Investigational Site
    Fürstenfeldbruck, Germany
  • Boehringer Ingelheim Investigational Site
    Gransee, Germany
  • Boehringer Ingelheim Investigational Site
    Hameln, Germany
  • Boehringer Ingelheim Investigational Site
    Heidelberg, Germany
  • Boehringer Ingelheim Investigational Site
    Jena, Germany
  • Boehringer Ingelheim Investigational Site
    Kassel, Germany
  • Boehringer Ingelheim Investigational Site
    Kiel, Germany
  • Boehringer Ingelheim Investigational Site
    Koblenz, Germany
  • Boehringer Ingelheim Investigational Site
    Korbach, Germany
  • Boehringer Ingelheim Investigational Site
    Köln, Germany
  • Boehringer Ingelheim Investigational Site
    Leipzig, Germany
  • Boehringer Ingelheim Investigational Site
    Ludwigsburg, Germany
  • Boehringer Ingelheim Investigational Site
    Mannheim, Germany
  • Boehringer Ingelheim Investigational Site
    Minden, Germany
  • Boehringer Ingelheim Investigational Site
    Möckmühl, Germany
  • Boehringer Ingelheim Investigational Site
    Mönchengladbach, Germany
  • Boehringer Ingelheim Investigational Site
    München, Germany
  • Boehringer Ingelheim Investigational Site
    Offenbach, Germany
  • Boehringer Ingelheim Investigational Site
    Paderborn, Germany
  • Boehringer Ingelheim Investigational Site
    Ravensburg, Germany

Showing the first 100 of 177 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18;367(9510):569-78. doi: 10.1016/S0140-6736(06)68147-6. PubMed 16488800 ↗
  • Zalewski J, Bogaerts K, Desmet W, Sinnaeve P, Berger P, Grines C, Danays T, Armstrong P, Van de Werf F. Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. J Am Coll Cardiol. 2011 May 10;57(19):1867-73. doi: 10.1016/j.jacc.2010.10.061. PubMed 21545942 ↗
  • Jarai R, Huber K, Bogaerts K, Sinnaeve PR, Ezekowitz J, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI investigators. Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial. Crit Care Med. 2010 Sep;38(9):1793-801. doi: 10.1097/CCM.0b013e3181eaaf2a. Erratum In: Crit Care Med. 2010 Dec;38(12):2430. PubMed 20562693 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003 and a primary completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Nov 2003
Primary completion
Jul 2006
Last update
Oct 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
No changes since tracking began. The registry record was last updated on Oct 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00168792
Collaborators
Genentech, Inc.
First posted
Sep 15, 2005
Start date
Nov 2003
Primary completion
Jul 2006
Last update
Oct 29, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion